GET DAILY SIGNALS10x Genomics (TXG): Is a Move to $105 Realistic After Its +348% Surge?
Key Takeaways
- The central target of $105 is the average of verified analyst price targets that sit above the current market price, not the headline consensus.
- The overall mean of all analyst targets is roughly $77, with a wide range from about $50 to $110, reflecting significant disagreement.
- With the stock near $73, reaching $105 would require a gain of roughly 44% — a very large move, though the stock traded above $100 as recently as early October 2026.
- Bullish support comes from the Atera platform launch, growing spatial biology demand, and positioning around AI-driven drug discovery, alongside notable institutional buying.
- The biggest risks are persistent losses, extreme volatility, a rich valuation, and competitive pressure in single-cell and spatial genomics.
- For more context, explore the Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
- You can also explore Trending AI Robots to see AI-driven trading strategies across the market.
Analyst Price Targets and the Street's View
Roughly 18 to 19 analysts cover TXG, according to S&P Global and Zacks data. Their targets span a wide band from a low near $50 to a high near $110, with an overall average price target of approximately $77. Because that average sits only about 5% above the recent price — too small to pose a meaningful "can it reach" question — the central target used here is instead the average of the verified targets that sit above the current price. Those higher-end targets, which include a $100 target from an October 2026 Buy rating and the $110 top of the range, average out to roughly $105. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ratings are skewed cautious rather than uniformly bullish: the Street is split between Strong Buy/Buy calls and a large Hold contingent, with no formal Sell ratings. Barclays, Argus Research, Jefferies, Stephens, William Blair, and Canaccord Genuity have carried constructive or initiating Buy-style views during 2026, while UBS, RBC, Piper Sandler, Citi, Cowen, and Leerink have maintained or initiated Hold ratings. The wide $50–$110 range reflects a genuine debate about whether 10x Genomics' new product cycle justifies its re-rated multiple.
Where TXG Stands Today and the Path to $105
As of the late-October 2026 close, TXG traded near $72.96, within a 52-week range of $12.34 to $102.81. Reaching $105 would require a rise of about 44%, a very large move by any conventional measure. Notably, however, the stock touched its $102.81 52-week high on October 6 before a sharp selloff erased roughly a quarter of its value within weeks, so $105 lies just above a level the market has already visited. The path toward it would likely depend on whether the company's Atera platform and spatial portfolio convert analyst enthusiasm into sustained instrument placements and consumables revenue, rather than renewed momentum alone.
Factors That Could Support a Recovery
Several verified factors could support a recovery toward $105. The company is a leader in single-cell analysis through its Chromium platform and in spatial biology through Visium and Xenium, and the newer Atera platform has given analysts a tangible growth driver to model. Positioning around AI-enabled drug discovery has attracted renewed interest, including a sizable 2026 purchase of roughly 222,000 shares by ARK Investment Management. The balance sheet remains comparatively clean, with modest debt relative to equity and a meaningful cash position, giving the company room to invest through its current losses.
Key Risks That Could Stand in the Way
The obstacles are substantial. 10x Genomics remains unprofitable, posting a trailing-twelve-month net loss of roughly $75 million on about $617 million in revenue, with EPS (earnings per share) around -$0.61. The stock's five-year beta near 2.0 underscores its volatility, and its valuation already reflects considerable optimism about future growth that has not yet materialized on the bottom line. Competition in single-cell and spatial genomics could pressure pricing, and any slowdown in academic or biopharma research spending would weigh directly on instrument demand.
Technical Levels Worth Watching
The chart offers clear reference points. The $102.81 early-October high and the psychologically important $100 level form a durable resistance zone that a move toward $105 would need to clear. On the downside, the stock has repeatedly found support near the $67 area during October, a zone that has held through several sharp intraday declines. A sustained break below that support would undermine the bullish technical structure, while a reclaim of $100 would put the central target back in view.
Time Horizon and Catalysts to Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts may apply different assumptions. The most important near-term catalyst is the company's third-quarter earnings report, confirmed for November 5, 2026, which will test the Street's revenue and guidance expectations. Investors should also watch for analyst target revisions, commentary on Atera adoption and consumables pull-through, any changes in institutional positioning, and broader risk appetite for unprofitable, high-beta growth stocks.
Final Assessment
Whether 10x Genomics (TXG) can reach $105 depends less on sentiment than on execution. The target, derived from analyst targets above the current price, implies a roughly 44% advance from about $73 — a demanding climb, though one that merely retests territory the stock occupied in early October. Support comes from Atera, spatial biology momentum, and AI-adjacent demand, while unprofitability, a rich valuation, and intense volatility are the principal obstacles. With the average analyst target near $77 and individual estimates spanning $50 to $110, the Street itself is divided. The November earnings report and any guidance updates are the clearest near-term signposts for whether higher targets regain credibility.
Using Tickeron AI Tools for Research
When I analyze names with this level of volatility, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track shifting conditions across thousands of stocks and ETFs. The signals draw on technical behavior and AI-driven models to flag Buy, Sell, or Hold ideas, which helps me review opportunities and existing positions more efficiently than manual checks alone. This approach has become a regular part of how I stay on top of fast-moving ideas like TXG.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TXG in upward trend: price rose above 50-day moving average on October 26, 2026
TXG moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 56 cases where TXG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 205 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 196 of 232 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 10-day moving average for TXG crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.515) is normal, around the industry mean (3.847). P/E Ratio (-123.661) is within average values for comparable stocks, (1.909). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement